Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
65.83
Nov 19 • 3:59 PM ET Dollar change-2.46 Percentage change(-3.60%)
Aftermarket Close
65.37
Aftermarket • 7:30 PM ET Dollar change-0.46 Percentage change(-0.69%)
Index
RUI
Market Cap
16.06B
Enterprise Value
15.33B
Income
885.14M
Sales
2.50B
Book/sh
7.49
Cash/sh
3.66
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
1077
IPO
Apr 11, 2000
P/E
19.70
Forward P/E
15.49
PEG
0.79
P/S
6.43
P/B
8.78
P/C
18.01
P/FCF
13.83
EV/EBITDA
14.86
EV/Sales
6.14
Quick Ratio
3.14
Current Ratio
3.21
Debt/Eq
0.09
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
3.34
EPS next Y
4.25
EPS next Q
1.00
EPS this Y
20.50%
EPS next Y
14.47%
EPS next 5Y
19.51%
EPS past 3/5Y
70.35% 51.19%
Sales past 3/5Y
12.93% 18.63%
EPS Y/Y TTM
40.53%
Sales Y/Y TTM
9.12%
EPS Q/Q
22.71%
Sales Q/Q
10.19%
Insider Own
3.22%
Insider Trans
-1.76%
Inst Own
103.95%
Inst Trans
-1.08%
ROA
33.17%
ROE
44.32%
ROIC
44.34%
Gross Margin
96.26%
Oper. Margin
40.21%
Profit Margin
35.45%
SMA20
-4.03%
SMA50
4.44%
SMA200
24.81%
Trades
Shs Outstand
244.68M
Shs Float
236.15M
52W High
73.69 -10.67%
52W Low
39.71 65.78%
Volatility
3.44% 3.43%
ATR (14)
2.23
RSI (14)
46.81
Beta
0.43
Rel Volume
1.13
Avg Volume
2.43M
Volume
2,741,885
Perf Week
-5.74%
Perf Month
1.94%
Perf Quarter
21.73%
Perf Half Y
32.59%
Perf YTD
50.19%
Perf Year
56.22%
Perf 3Y
211.55%
Perf 5Y
265.11%
Perf 10Y
288.15%
Prev Close
68.29
Price
65.83
Change %
-3.60%
Consensus
Buy
Avg. Price Target
$62.08
Implied Upside
-5.7%
Analysts14incl. previous ratings
Rating Distribution2 Buy · 11 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 19, 2026Initiated
BMO logoBBMO Capital Markets
Market Perform$54-18.0%
Aug 06, 2026Downgrade
LLeerink Partners
Outperform → Market Perform$52-21.0%
Jun 25, 2026Resumed
TFC logoTTruist
Hold$54-18.0%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$48-27.1%
Jan 05, 2026Downgrade
BAC logoBBofA Securities
Neutral → Underperform$41-37.7%
Nov 18, 2025Initiated
WWolfe Research
Peer Perform
Nov 03, 2025Downgrade
GGuggenheim
Buy → Neutral
Oct 21, 2025Upgrade
LLeerink Partners
Market Perform → Outperform$48-27.1%
Sep 19, 2025Resumed
BCS logoBBarclays
Equal Weight$40-39.2%
Sep 17, 2025Resumed
BCS logoBBarclays
Equal Weight$40-39.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beckerle Mary CDirectorAug 10 '26Sale53.669,812526,51216,079Aug 12 07:34 PM
MARY BECKERLEDirectorAug 10 '26Proposed Sale53.669,812526,496Aug 10 04:15 PM
WYSZOMIERSKI JACK LDirectorJun 01 '26Sale50.553,925198,409284,384Jun 03 06:52 PM
Eckhardt Sue GailDirectorJun 01 '26Sale50.149,812491,97416,079Jun 03 06:51 PM
Eckhardt Sue GailDirectorJun 01 '26Proposed Sale50.879,812499,136Jun 01 04:16 PM
JACK L WYSZOMIERSKIDirectorJun 01 '26Proposed Sale50.553,925198,409Jun 01 04:04 PM
Aftab DanaEVP, Research and DevelopmentMay 26 '26Sale50.3543,4512,187,758594,741May 28 06:25 PM
DANA T AFTABOfficerMay 26 '26Proposed Sale50.3543,4512,187,758May 26 04:09 PM
Haley Patrick J.EVP, CommercialMay 20 '26Sale49.8132,1101,599,399357,638May 22 05:01 PM
PATRICK JOSEPH HALEYOfficerMay 20 '26Proposed Sale49.8132,1101,599,444May 20 04:31 PM
Senner Christopher J.EVP and CFOMay 18 '26Sale50.0034,9011,745,050952,317May 19 06:58 PM
Hefti BrendaSVP and General CounselMay 18 '26Sale50.216,625332,641106,762May 19 06:58 PM
CHRISTOPHER J SENNEROfficerMay 18 '26Proposed Sale50.0034,9011,745,179May 18 04:49 PM
BRENDA JOY HEFTIOfficerMay 18 '26Proposed Sale50.216,625332,641May 18 04:23 PM
BOMBORA RISE FOUNDATIONFamily foundation of the CEO oMay 14 '26Proposed Sale50.91100,0005,091,190May 14 04:30 PM
Beckerle Mary CDirectorMay 07 '26Option Exercise23.243,85689,61325,236May 08 07:03 PM
Beckerle Mary CDirectorMay 07 '26Sale48.457,712373,64617,524May 08 07:03 PM
Freire Maria CDirectorMay 07 '26Option Exercise19.7720,634407,934121,453May 08 07:03 PM
Freire Maria CDirectorMay 07 '26Sale46.0020,634949,164100,819May 08 07:03 PM
POSTE GEORGEDirectorMay 07 '26Sale45.7160,0002,742,600118,832May 08 07:03 PM
MARY BECKERLEDirectorMay 07 '26Proposed Sale48.457,712373,646May 07 04:39 PM
GEORGE H POSTEDirectorMay 07 '26Proposed Sale45.7160,0002,742,468May 07 04:36 PM
MARIA C FREIREDirectorMay 07 '26Proposed Sale46.0020,634949,164May 07 04:07 PM
Aftab DanaEVP, Research and DevelopmentFeb 24 '26Sale44.5047,9182,132,351616,106Feb 26 06:41 PM
DANA T AFTABOfficerFeb 24 '26Proposed Sale44.5047,9182,132,351Feb 24 04:05 PM
Aftab DanaEVP, Research and DevelopmentFeb 19 '26Sale44.3529,8731,324,868664,024Feb 23 06:50 PM
WYSZOMIERSKI JACK LDirectorFeb 18 '26Option Exercise19.7720,634407,934379,516Feb 20 08:36 PM
WYSZOMIERSKI JACK LDirectorFeb 18 '26Sale44.0199,5744,382,252279,942Feb 20 08:36 PM
Smith JulieDirectorFeb 18 '26Option Exercise20.1164,1171,289,29864,677Feb 19 07:18 PM
Smith JulieDirectorFeb 17 '26Option Exercise18.1942,422771,65663,012Feb 19 07:18 PM
Smith JulieDirectorFeb 18 '26Sale44.4464,1172,849,20020,590Feb 19 07:18 PM
Smith JulieDirectorFeb 17 '26Sale43.3342,4221,838,14520,590Feb 19 07:18 PM
DANA T AFTABOfficerFeb 19 '26Proposed Sale44.3529,8731,324,868Feb 19 04:06 PM
Senner Christopher J.EVP and CFOFeb 13 '26Sale43.0034,2781,473,9541,042,579Feb 18 08:49 PM
Senner Christopher J.EVP and CFOFeb 17 '26Sale43.6730,6171,337,044976,092Feb 18 08:49 PM
Haley Patrick J.EVP, CommercialFeb 17 '26Sale43.5267,8142,950,941381,908Feb 18 08:49 PM
MORRISSEY MICHAELPresident and CEOFeb 13 '26Option Exercise21.31494,70010,542,0572,319,941Feb 18 08:49 PM
Eckhardt Sue GailDirectorFeb 13 '26Sale43.793,856168,85417,524Feb 18 08:49 PM
Oliver BobDirectorFeb 13 '26Option Exercise19.289,088175,21751,370Feb 18 08:48 PM
Oliver BobDirectorFeb 13 '26Sale43.8130,2501,325,33921,120Feb 18 08:48 PM
Hefti BrendaSVP and General CounselFeb 18 '26Sale44.0118,669821,62396,512Feb 18 08:48 PM
JULIE ANNE SMITHDirectorFeb 18 '26Proposed Sale44.4464,1172,849,200Feb 18 05:55 PM
BRENDA JOY HEFTIOfficerFeb 18 '26Proposed Sale44.0118,669821,664Feb 18 04:30 PM
JACK L WYSZOMIERSKIDirectorFeb 18 '26Proposed Sale44.0199,5744,382,507Feb 18 04:01 PM
JULIE ANNE SMITHDirectorFeb 17 '26Proposed Sale44.3342,4221,880,440Feb 17 06:47 PM
CHRISTOPHER J SENNEROfficerFeb 17 '26Proposed Sale43.6730,6171,337,035Feb 17 06:45 PM
PATRICK JOSEPH HALEYOfficerFeb 17 '26Proposed Sale43.5267,8142,951,083Feb 17 06:43 PM
Eckhardt Sue GailDirectorFeb 13 '26Proposed Sale42.893,856165,384Feb 13 04:39 PM
CHRISTOPHER J SENNEROfficerFeb 13 '26Proposed Sale43.0034,2781,473,964Feb 13 04:07 PM
ROBERT L OLIVERDirectorFeb 13 '26Proposed Sale43.8230,2501,325,408Feb 13 04:07 PM
BOMBORA RISE FOUNDATIONFamily foundation of the CEO oFeb 12 '26Proposed Sale43.255,000216,250Feb 12 07:02 PM
Haley Patrick J.OfficerNov 20 '25Proposed Sale41.7810,648444,873Dec 12 06:08 PM
JOHNSON DAVID EDWARDDirectorNov 25 '25Buy43.1227,5321,187,2351,553,262Nov 26 04:05 PM
Haley Patrick J.EVP, CommercialNov 20 '25Sale41.8834,1871,431,7570Nov 24 07:47 PM
Haley Patrick J.EVP, CommercialNov 21 '25Sale42.5828,0431,194,071374,029Nov 24 07:47 PM
Haley Patrick J.EVP, CommercialNov 20 '25Sale42.1110,000421,100402,072Nov 24 07:47 PM
PATRICK JOSEPH HALEYOfficerNov 20 '25Proposed Sale42.1110,000421,052Nov 20 04:02 PM
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Co-Founder & Independent Chair of the BoardDr. Stelios Papadopoulos Ph.D.
CEODr. Michael M. Morrissey Ph.D.
Executive VP & CFOMr. Christopher J. Senner
Ph.D.Dr. Brenda J. Hefti J.D.
Executive Vice President of Research & DevelopmentDr. Dana T. Aftab Ph.D.